title: Effects of prophylactic and therapeutic teriflunomide in transcranial magnetic stimulation-induced motor-evoked potentials in the dark agouti rat model of experimental autoimmune encephalomyelitis.
abstract: Teriflunomide is a once-daily oral immunomodulatory agent recently approved in the United States for the treatment of relapsing multiple sclerosis (RMS). This study investigated neurophysiological deficits in descending spinal cord motor tracts during experimental autoimmune encephalomyelitis (EAE; a model of multiple sclerosis) and the functional effectiveness of prophylactic or therapeutic teriflunomide treatment in preventing the debilitating paralysis observed in this model. Relapsing-remitting EAE was induced in Dark Agouti rats using rat spinal cord homogenate. Animals were treated with oral teriflunomide (10 mg/kg daily) prophylactically, therapeutically, or with vehicle (control). Transcranial magnetic motor-evoked potentials were measured throughout the disease to provide quantitative assessment of the neurophysiological status of descending motor tracts. Axonal damage was quantified histologically by silver staining. Both prophylactic and therapeutic teriflunomide treatment significantly reduced maximum EAE disease scores (P < 0.0001 and P = 0.0001, respectively) compared with vehicle-treated rats. Electrophysiological recordings demonstrated that both teriflunomide treatment regimens prevented a delay in wave-form latency and a decrease in wave-form amplitude compared with that observed in vehicle-treated animals. A significant reduction in axonal loss was observed with both teriflunomide treatment regimens compared with vehicle (P < 0.0001 and P = 0.0014, respectively). The results of this study suggest that therapeutic teriflunomide can prevent the deficits observed in this animal model in descending spinal cord motor tracts. The mechanism behind reduced axonal loss and improved motor function may be primarily the reduced inflammation and consequent demyelination observed in these animals through the known effects of teriflunomide on impairing proliferation of stimulated T cells. These findings may have significant implications for patients with RMS.
authors.affiliation: Sanofi, Bridgewater, New Jersey.
authors.forename: Deborah
authors.initials: D
authors.lastname: Iglesias-Bregna
authors.forename: Susan
authors.initials: S
authors.lastname: Hanak
authors.forename: Zhongqi
authors.initials: Z
authors.lastname: Ji
authors.forename: Margaret
authors.initials: M
authors.lastname: Petty
authors.forename: Li
authors.initials: L
authors.lastname: Liu
authors.forename: Donghui
authors.initials: D
authors.lastname: Zhang
authors.forename: Kathleen
authors.initials: K
authors.lastname: McMonagle-Strucko
mesh_terms: D000818:Animals; D003437:Crotonates / Q000494:pharmacology / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000503:physiopathology / Q000628:therapy*; D019054:Evoked Potentials, Motor / Q000187:drug effects / Q000502:physiology*; D006885:Hydroxybutyrates; D008297:Male; D009570:Nitriles; D051381:Rats; D014052:Toluidines / Q000494:pharmacology / Q000627:therapeutic use*; D050781:Transcranial Magnetic Stimulation / Q000379:methods; D016896:Treatment Outcome
chemical_list: D003437:Crotonates; D006885:Hydroxybutyrates; D009570:Nitriles; D014052:Toluidines; C527525:teriflunomide